Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor & fibroid embolization cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (118 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 274 | 33% |
| 2020 | 2 | 229 | 36% |
| 2021 | 1 | 261 |
Chemo- and radioembolization of liver tumors, uterine fibroid and other organ embolization (one code covers all). Professional codes (what the surgeon bills): CPT 37243.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Jersey; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 22 | 1,661+10%/yr | +10%/yr | 0.9 | 48% | 3,360 in 2030+12%/yr |
| Pennsylvania | 19 | 908 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 124 | 7,0630%/yr | 0%/yr | 7.10.8× | 39% | 8,480 in 2030+3.1%/yr |
| Tumor ablation |
Tumor & fibroid embolization in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with New York
| ≈ 530 |
| – |
| 2026 est. | ≈ 580 | – |
| 39% |
| 2022 | 2 | 262 | 41% |
| 2023 | 4 | 353 | 43% |
| 2024 | 4 | 287 | 45% |
| 2025 from claims | – | 534 432–627 | 46% |
| 2026 forecast | – | 583 457–732 | 46% |
| 2027 forecast | – | 635 471–839 | 47% |
| 2028 forecast | – | 691 489–954 | 47% |
| 2029 forecast | – | 753 511–1,079 | 47% |
| 2030 forecast | – | 819 537–1,216 | 48% |
In 2025, 4% inpatient hospital, 74% hospital outpatient, 22% office. The share outside the hospital has moved +22 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~580 | ~19 | ~400 | ~160 |
| 2027 · ~630 | ~20 | ~420 | ~200 |
| 2028 · ~690 | ~21 | ~440 | ~230 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: office about 33% (22% in 2025), hospital outpatient about 64% (74% in 2025).
| −0.7%/yr |
| 0.7 |
| 27% |
| 1,830 in 2030+12%/yr |
| Massachusetts | 12 | 677+16%/yr | +16%/yr | 0.7 | 46% | 1,170 in 2030+9.5%/yr |
| Connecticut | 3 | 119−5.9%/yr | −5.9%/yr | 0.4 | 0% | 170 in 2030+6.1%/yr |
| 0 |
| 107−1.1%/yr |
| −1.1%/yr |
| 0.10.3× |
| 0% |
| 120 in 2030+1.8%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Exact Sciences leads with 52% of company spending on these surgeons in 2025, +3 pts on 2024.
In 2025, 18 companies reported engagement with New Jersey’s surgeons worth $475K in consulting, speaking, meals and travel tied to these products, about $119K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 16 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.